Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

0.4666

+0.0036 (0.78%)

Nov 11, 2025, 4:00 PM EST - Market closed

Virax Biolabs Group Employees

Virax Biolabs Group had 19 employees as of March 31, 2025. The number of employees increased by 2 or 11.76% compared to the previous year.

Employees

19

Change (1Y)

2

Growth (1Y)

11.76%

Revenue / Employee

$333

Profits / Employee

-$319,013

Market Cap

2.03M

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2025	19	2	11.76%
Mar 31, 2024	17	6	54.55%
Mar 31, 2023	11	6	120.00%
Mar 31, 2022	5	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

VRAX News

8 days ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
2 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
3 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
4 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
8 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
8 months ago - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes - PRNewsWire
8 months ago - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - PRNewsWire
8 months ago - Virax Biolabs to Present at 19th World Immune Regulation Meeting - PRNewsWire